Moumita Hazra
INTRODUCTION
Remogliflozin, a selective insulin independent sodium glucose co - transporter subtype 2 (SGLT2) inhibitor, inhibits reabsorption of renal glucose, lowers blood sugar, and causes glucosuria, in type II diabetes mellitus patients. Metformin, as a combination anti-diabetic drug, lowers serum glucose levels; by the activation of 5’ Adenosine Monophosphate (AMP) activated protein kinase.
OBJECTIVES
The objective of this Evidence-Based Medicine research series was the rational pharmacotherapeutic appraisal of the diabetological pharmacovigilance of the combination therapies of 50 mg or 75 mg remogliflozin with 500 mg metformin among type II diabetics, in tertiary care medical college hospitals, along global pharmacoepidemiology, and an anti - diabetic tertiary medical healthcare patient satisfaction evaluation.
METHODS
125 new early moderate grade type II diabetes mellitus patients were prescribed oral metformin 500 mg once daily for 30 days. Then, 100 diabetics uncontrolled with metformin monotherapy, were prescribed oral 50 mg remogliflozin with 500 mg metformin once daily, for 15 days; who were subsequently prescribed oral 75 mg remogliflozin with 500 mg metformin once daily for 15 days. The safety assessment, along with blood sugar and HbA1c levels and urine routine examination, on day 0, day 30, day 46, day 60, and further follow - up, were recorded and statistically analysed. An anti - diabetic tertiary medical healthcare patient satisfaction evaluation was also performed by patient response to different attributes of anti-diabetic treatment.
RESULTS
The adverse effects with the combination therapy of 50 mg remogliflozin with metformin and the combination therapy of 75 mg remogliflozin with metformin were statistically non - significant; hence both were safe and tolerable. All the patients were satisfied with each anti-diabetic medical healthcare attribute.
CONCLUSION
The combination therapy of 50 mg remogliflozin and metformin as well as the combination therapy of 75 mg remogliflozin and metformin were safe and tolerable. There was ample anti - diabetic medical healthcare satisfaction.
